A Multivalent MRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Feb 26

PMID 40006578

Authors

Shang Liu

Jie Wang

Yunxuan Li

Muhan Wang

Pei Du

Zhijie Zhang

Wenguo Li

Rongchen Sun

Mingtao Fan

Meijia Yang

Hongping Yin

Affiliations

Soon will be listed here.

Abstract

: In chronic hepatitis B infection (CHB), the hepatitis B surface antigen (HBsAg) continuously exhausts the hepatitis B surface antibody (HBsAb), which leads to the formation of immune tolerance. Accordingly, the hepatitis B virus (HBV) infection can be blocked by inhibiting the binding of the hepatitis B surface pre-S1/pre-S2 antigen to the hepatocyte receptor NTCP, but the clinical cure rate of pre-S-based vaccines for CHB is limited. : In this study, we designed and prepared multivalent hepatitis B therapeutic mRNA vaccines encoding three hepatitis B surface antigen proteins (L, M, and S) at the cell membrane, verified via in vitro transfection and expression experiments. An in vivo immunization experiment in HBV transgenic (Tg) mice was first completed. Subsequently, an adeno-associated virus plasmid vector carrying the HBV1.2-fold genome (pAAV HBV1.2) model and the adeno-associated virus vector carrying HBV1.3-fold genome (rAAV HBV1.3) model were constructed and immunized with mRNA vaccines. The HBV antigen, antibodies, and HBV DNA in serum were detected. Indirect (enzyme-linked immunosorbent assay) ELISA were made to analyze the activated antigen-specific IgG in HBV Tg mice. Antigen-dependent T-cell activation experiments were carried out, as well as the acute toxicity tests in mice. : The L protein/pre-S antigens could be stably presented at the cell membrane with the support of the S protein (and M protein). After vaccinations, the vaccines effectively reactivated the production of high levels of HBsAb, disrupted immune tolerance, and activated the production of high-affinity antibodies against structural pre-S antigen in HBV Tg mice. The HBsAg seroconversion and serum HBV DNA clearance were achieved in two HBV mice models. Furthermore, pre-S antigen-dependent T-cell response against HBV infection was confirmed. The therapeutic vaccine also showed safety in mice. : A novel therapeutic mRNA vaccine was developed to break through HBsAg-mediated immune tolerance and treat CHB by stably presenting the pre-S antigen at the membrane, and the vaccine has great potential for the functional cure of CHB.

References

Yato K, Matsuda M, Fukano K, Tanaka T, Moriishi K, Nishitsuji H . Identification of neutralizing epitopes in the preS2 domain of the hepatitis B virus. Virus Res. 2022; 323:199014. PMC: 10194358. DOI: 10.1016/j.virusres.2022.199014. View

Yum J, Ahn B, Jo H, Kim D, Kim K, Kim H . Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection. Clin Vaccine Immunol. 2011; 19(2):120-7. PMC: 3272936. DOI: 10.1128/CVI.05355-11. View

Ho J, Jeevan-Raj B, Netter H . Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses. 2020; 12(2). PMC: 7077199. DOI: 10.3390/v12020126. View

Vandepapeliere P, Lau G, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T . Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine. 2007; 25(51):8585-97. DOI: 10.1016/j.vaccine.2007.09.072. View

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

Zhu Y, Yu M, Aisikaer M, Zhang C, He Y, Chen Z . Contriving a novel of CHB therapeutic vaccine based on IgV_CTLA-4 and L protein via immunoinformatics approach. J Biomol Struct Dyn. 2023; 42(12):6323-6341. DOI: 10.1080/07391102.2023.2234043. View

Wherry E, Kurachi M . Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8):486-99. PMC: 4889009. DOI: 10.1038/nri3862. View

Cornberg M, Lok A, Terrault N, Zoulim F . Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol. 2019; 72(3):539-557. DOI: 10.1016/j.jhep.2019.11.003. View

Roier S, Prasad V, McNeal M, Lee K, Petsch B, Rauch S . mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents. NPJ Vaccines. 2023; 8(1):190. PMC: 10739717. DOI: 10.1038/s41541-023-00790-z. View

10.

Clayton R, Owsianka A, Patel A . Evidence for structural differences in the S domain of L in comparison with S protein of hepatitis B virus. J Gen Virol. 2001; 82(Pt 7):1533-1541. DOI: 10.1099/0022-1317-82-7-1533. View

11.

Neurath A, Kent S, Strick N, Parker K, Courouce A, Riottot M . Antibodies to synthetic peptides from the pre-S1 and pre-S2 regions of one subtype of the hepatitis B virus (HBV) envelope protein recognize all HBV subtypes. Mol Immunol. 1987; 24(9):975-80. DOI: 10.1016/0161-5890(87)90009-5. View

12.

Roggendorf H, Shouval D, Roggendorf M, Gerken G . Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrio) of Chronically HBV Infected Patients. J Pers Med. 2024; 14(4). PMC: 11050803. DOI: 10.3390/jpm14040364. View

13.

He J, Miao R, Chen Y, Wang H, Liu M . The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma. Immunology. 2023; 171(4):445-463. DOI: 10.1111/imm.13738. View

14.

Jaroszewicz J, Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R . Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010; 52(4):514-22. DOI: 10.1016/j.jhep.2010.01.014. View

15.

Pawlotsky J . New hepatitis B drug development disillusions: time to reset?. Lancet Gastroenterol Hepatol. 2022; 8(2):192-197. DOI: 10.1016/S2468-1253(22)00341-7. View

16.

Ma H, Lim T, Leerapun A, Weltman M, Jia J, Lim Y . Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Rep. 2021; 3(6):100361. PMC: 8502773. DOI: 10.1016/j.jhepr.2021.100361. View

17.

Chen B, Chen Y, Li J, Wang C, Song W, Wen Y . A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. mBio. 2022; 13(4):e0161222. PMC: 9426588. DOI: 10.1128/mbio.01612-22. View

18.

De Pooter D, Pierson W, Pourshahian S, Dockx K, De Clerck B, Najera I . mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model. Vaccines (Basel). 2024; 12(3). PMC: 10976109. DOI: 10.3390/vaccines12030237. View

19.

Qi R, Fu R, Lei X, He J, Jiang Y, Zhang L . Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels. J Hepatol. 2024; 80(5):714-729. DOI: 10.1016/j.jhep.2023.12.032. View

20.

Wei J, Wang Y, Lu Z, Li G, Wang Y, Zhang Z . Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay. World J Gastroenterol. 2002; 8(2):276-81. PMC: 4658366. DOI: 10.3748/wjg.v8.i2.276. View